CRISPR Therapeutics AG — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
CRISPR reported Q3 2026 CASGEVY revenue of $99M (up 30% QoQ, 6x YoY), with new approvals in U.K. (children 5+), UAE, and Bahrain. FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. Cash position strengthened to $2,276.6M (vs. $1,975.8M Dec 2025) via $585.4M convertible notes issuance in March 2026. Net loss Q3 was $111.4M; R&D expenses $71.9M.
Why this rating
CASGEVY acceleration (now ~$400M run-rate, material to $4.1B market cap) plus pipeline momentum (CTX310 RMAT, zugo-cel data, CTX611 Phase 2 complete) represent meaningful progress. Diversifying revenue stream and regulatory validation matter significantly, though still pre-majority profitability.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.